Adrian L Harris

List of Publications by Year
in descending order

618	77,298	305 132	519 255
papers	citations	h-index	g-index

728	728	728	88189
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Autophagy Blockage Up-Regulates HLA-Class-I Molecule Expression in Lung Cancer and Enhances Anti-PD-L1 Immunotherapy Efficacy. Cancers, 2024, 16, 3272.	4.0	1
2	Metabolic Reprogramming in Colon Cancer Cells Persistently Infected with Newcastle Disease Virus. Cancers, 2023, 15, 811.	4.0	2
3	75th anniversary of the British Journal of Cancer. British Journal of Cancer, 2023, 128, 401-401.	5.7	0
4	Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?. British Journal of Cancer, 2023, 128, 958-966.	5.7	60
5	Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model. Cancers, 2023, 15, 1922.	4.0	2
6	GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner. Cancer Research, 2023, 83, 3400-3413.	0.6	3
7	Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities. British Journal of Cancer, 2023, 129, 897-899.	5.7	12
8	A Rab6 to Rab11 transition is required for dense-core granule and exosome biogenesis in Drosophila secondary cells. PLoS Genetics, 2023, 19, e1010979.	3.3	2
9	Investigations on Zinc Isotope Fractionation in Breast Cancer Tissue Using in vitro Cell Culture Uptake-Efflux Experiments. Frontiers in Medicine, 2022, 8, .	2.7	7
10	Novel humanized monoclonal antibodies for targeting hypoxic human tumors via two distinct extracellular domains of carbonic anhydrase IX. Cancer & Metabolism, 2022, 10, .	4.8	12
11	Proline synthesis through PYCR1 is required to support cancer cell proliferation and survival in oxygen-limiting conditions. Cell Reports, 2022, 38, 110320.	6.4	36
12	Targeting hypoxia regulated sodium driven bicarbonate transporters reduces triple negative breast cancer metastasis. Neoplasia, 2022, 25, 41-52.	7.2	13
13	Role of Hypoxia in the Interferon Response. Frontiers in Immunology, 2022, 13, .	5.0	8
14	Abstract 5813: Glycogen synthesis as potential novel target in triple negative breast cancer: Glycogen synthase 1 expression in human breast cancers and the impact of downregulation on proliferation of preclinical models. Cancer Research, 2022, 82, 5813-5813.	0.6	1
15	Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation. Cell Death and Disease, 2022, 13, .	8.5	13
16	Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast. Cancers, 2022, 14, 3916.	4.0	3
17	Survival Pathways of HIF-Deficient Tumour Cells: TCA Inhibition, Peroxisomal Fatty Acid Oxidation Activation and an AMPK-PGC-1Î± Hypoxia Sensor. Cells, 2022, 11, 3595.	4.8	1
18	Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes. Seminars in Cancer Biology, 2021, 72, 175-184.	14.2	12

#	Article	IF	Citations
19	Reciprocal interactions between tumour cell populations enhance growth and reduce radiation sensitivity in prostate cancer. Communications Biology, 2021, 4, .	4.5	34
20	Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast. British Journal of Cancer, 2021, 124, 1150-1159.	5.7	11
21	Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2459-2469.	6.4	53
22	The Landscape of the Heritable Cancer Genome. Cancer Research, 2021, 81, 2588-2599.	0.6	15
23	Elevated expression of the adhesion GPCR ADGRL4/ELTD1 promotes endothelial sprouting angiogenesis without activating canonical GPCR signalling. Scientific Reports, 2021, 11, .	3.7	14
24	Unveiling Cancer Metabolism through Spontaneous and Coherent Raman Spectroscopy and Stable Isotope Probing. Cancers, 2021, 13, 1718.	4.0	50
25	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. Journal of Experimental and Clinical Cancer Research, 2021, 40, .	11.5	18
26	Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. JCI Insight, 2021, , .	5.5	4
27	Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. British Journal of Cancer, 2021, 125, 534-546.	5.7	12
28	Machine learning to guide the use of adjuvant therapies for breast cancer. Nature Machine Intelligence, 2021, 3, 716-726.	17.4	30
29	Differential effects of HIF2Î± antagonist and HIF2Î± silencing in renal cancer and sensitivity to repurposed drugs. BMC Cancer, 2021, 21, .	3.0	4
30	The prognostic and therapeutic implications of distinct patterns of argininosuccinate synthase 1 (ASS1) and arginase-2 (ARG2) expression by cancer cells and tumor stroma in non-small-cell lung cancer. Cancer & Metabolism, 2021, 9, .	4.8	22
31	ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression. Molecular Cancer Research, 2021, 19, 1957-1969.	2.9	5
32	Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer. British Journal of Cancer, 2021, 126, 551-561.	5.7	37
33	ELTD1 Activation Induces an Endothelial-EMT Transition to a Myofibroblast Phenotype. International Journal of Molecular Sciences, 2021, 22, 11293.	4.5	8
34	Hypoxia Regulates Endogenous Double-Stranded RNA Production via Reduced Mitochondrial DNA Transcription. Frontiers in Oncology, 2021, 11, .	2.7	16
35	Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging. British Journal of Cancer, 2021, 126, 598-605.	5.7	4
36	Partial Breast Reconstruction with Lateral Chest Wall Perforator Flap to Facilitate Breast Conservation in Breast Cancer: First 100 Cases with Cancer Outcomes at 8 Years Follow-Up and the Lessons Learned. Cancer Management and Research, 2021, Volume 13, 9453-9466.	1.9	8

#	Article	IF	Citations
37	The onset of circulation triggers a metabolic switch required for endothelial to hematopoietic transition. Cell Reports, 2021, 37, 110103.	6.4	18
38	Comprehensive Imaging Characterization of Colorectal Liver Metastases. Frontiers in Oncology, 2021, 11, .	2.7	9
39	Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. British Journal of Cancer, 2020, 122, 258-265.	5.7	33
40	Disruption of hypoxia-inducible fatty acid binding protein 7 induces beige fat-like differentiation and thermogenesis in breast cancer cells. Cancer & Metabolism, 2020, 8, .	4.8	11
41	The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer. PLoS ONE, 2020, 15, e0236187.	2.5	21
42	Hypoxia Induces Transcriptional and Translational Downregulation of the Type I IFN Pathway in Multiple Cancer Cell Types. Cancer Research, 2020, 80, 5245-5256.	0.6	55
43	Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion. British Journal of Cancer, 2020, 123, 137-147.	5.7	20
44	RHOQ is induced by DLL4 and regulates angiogenesis by determining the intracellular route of the Notch intracellular domain. Angiogenesis, 2020, 23, 493-513.	7.4	20
45	COVID-19 and cancer research. British Journal of Cancer, 2020, 123, 689-690.	5.7	17
46	Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Scientific Reports, 2020, 10, .	3.7	11
47	Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration. British Journal of Cancer, 2020, 122, 1205-1210.	5.7	28
48	Clinical strategies to inhibit tumor vascularization. , 2020, , 147-176.		1
49	Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. British Journal of Cancer, 2020, 124, 494-505.	5.7	74
50	Tumour subregion analysis of colorectal liver metastases using semi-automated clustering based on DCE-MRI: Comparison with histological subregions and impact on pharmacokinetic parameter analysis. European Journal of Radiology, 2020, 126, 108934.	3.1	6
51	HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. Journal of Clinical Investigation, 2020, 130, 5074-5087.	9.1	224
52	Glutamine deprivation alters the origin and function of cancer cell exosomes. EMBO Journal, 2020, 39, .	7.4	77
53	ADGRL4/ELTD1 is a highly conserved angiogenesis-associated orphan adhesion GPCR that emerged with the first vertebrates and comprises 3 evolutionary variants. BMC Evolutionary Biology, 2019, 19, .	3.4	10
54	BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nature Communications, 2019, 10, .	14.1	134

#	Article	IF	Citations
55	Landscape of transcriptomic interactions between breast cancer and its microenvironment. Nature Communications, 2019, 10, .	14.1	16
56	Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. Medical Oncology, 2019, 36, .	2.5	40
57	Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy. Molecular Cancer Therapeutics, 2019, 18, 2030-2042.	1.7	32
58	FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma. Experimental Lung Research, 2019, 45, 76-83.	1.4	19
59	Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12452-12461.	7.7	95
60	Adaptation to HIF1Î± Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism. Molecular Cancer Research, 2019, 17, 1531-1544.	2.9	20
61	ATF4, Hypoxia and Treatment Resistance in Cancer. Cancer Drug Discovery and Development, 2019, , 75-108.	0.0	2
62	ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile. Metabolites, 2019, 9, 287.	3.5	17
63	3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers. Molecular Cancer Therapeutics, 2019, 18, 376-388.	1.7	17
64	Endogenous miRNA sponges mediate the generation of oscillatory dynamics for a non-coding RNA network. Journal of Theoretical Biology, 2019, 481, 54-60.	1.8	4
65	High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer. British Journal of Cancer, 2019, 122, 245-257.	5.7	26
66	Development of cancer metabolism as a therapeutic target: new pathways, patient studies, stratification and combination therapy. British Journal of Cancer, 2019, 122, 1-3.	5.7	27
67	Non-angiogenic tumours and their influence on cancer biology. Nature Reviews Cancer, 2018, 18, 323-336.	24.2	117
68	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002279.	1.4	15
69	A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 2018, 118, 770-776.	5.7	10
70	SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy. Investigational New Drugs, 2018, 36, 773-781.	2.6	12
71	miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense. Cancer Research, 2018, 78, 501-515.	0.6	104
72	Advances in Hypoxia-Inducible Factor Biology. Cell Metabolism, 2018, 27, 281-298.	26.3	620

#	Article	IF	Citations
73	Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors. Nature Communications, 2018, 9, .	14.1	100
74	Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo. British Journal of Cancer, 2018, 119, 622-630.	5.7	93
75	Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metabolism, 2018, 28, 679-688.e4.	26.3	97
76	Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis, 2018, 21, 425-532.	7.4	445
77	The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6225-6230.	7.7	45
78	Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases. Clinical Cancer Research, 2018, 24, 4694-4704.	6.4	13
79	Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer. International Journal of Molecular Sciences, 2018, 19, 240.	4.5	21
80	A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis. Frontiers in Chemistry, 2018, 6, .	3.6	36
81	RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. PLoS ONE, 2018, 13, e0191890.	2.5	23
82	miR-193a-3p interaction with HMGB1 downregulates human endothelial cell proliferation and migration. Scientific Reports, 2017, 7, .	3.7	35
83	A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1. Genes and Development, 2017, 31, 353-369.	4.8	168
84	A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. Clinical Cancer Research, 2017, 23, 4761-4768.	6.4	95
85	In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer. Molecular Cancer, 2017, 16, .	29.8	23
86	Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab. EJNMMI Research, 2017, 7, .	2.7	2
87	Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 43, 137-153.	2.1	6
88	Single-cell heterogeneity in ductal carcinoma in situ of breast. Modern Pathology, 2017, 31, 406-417.	5.0	40
89	Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget, 2017, 8, 40115-40131.	1.7	34
90	Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation. Oncotarget, 2017, 8, 49484-49501.	1.7	65

#	Article	IF	Citations
91	Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget, 2017, 8, 78870-78881.	1.7	9
92	Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. Genome Biology, 2016, 17, .	8.4	71
93	Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM). Medicine (United States), 2016, 95, e2924.	1.3	23
94	Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth. Cancer Research, 2016, 76, 3744-3755.	0.6	79
95	Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the Spot. Cell Metabolism, 2016, 23, 580-589.	26.3	206
96	Labeling and preliminary in vivo assessment of niobium-labeled radioactive species: A proof-of-concept study. Nuclear Medicine and Biology, 2016, 43, 280-287.	0.2	13
97	Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. EBioMedicine, 2016, 10, 109-116.	10.0	28
98	The Role of pH Regulation in Cancer Progression. Recent Results in Cancer Research, 2016, , 93-134.	0.0	12
99	Imaging oligometastatic cancer before local treatment. Lancet Oncology, The, 2016, 17, e406-e414.	21.9	19
100	MEF2 transcription factors are key regulators of sprouting angiogenesis. Genes and Development, 2016, 30, 2297-2309.	4.8	63
101	Normal tissue radioprotection by amifostine via Warburg-type effects. Scientific Reports, 2016, 6, .	3.7	29
102	Why some tumours trigger neovascularisation and others donâ€™t: the story thus far. Chinese Journal of Cancer, 2016, 35, .	2.3	15
103	Methods: Using Three-Dimensional Culture (Spheroids) as an In Vitro Model of Tumour Hypoxia. Advances in Experimental Medicine and Biology, 2016, , 167-196.	0.0	50
104	Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy. Journal of Molecular Medicine, 2016, 94, 137-154.	3.6	180
105	Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. BMC Cancer, 2016, 16, .	3.0	46
106	Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer & Metabolism, 2016, 4, .	4.8	190
107	The tumour hypoxia induced non-coding transcriptome. Molecular Aspects of Medicine, 2016, 47-48, 35-53.	9.3	99
108	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	13.8	4,327

#	Article	IF	Citations
109	Antiangiogenic therapy in oncology: current status and future directions. Lancet, The, 2016, 388, 518-529.	35.3	659
110	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2016, 14, 169-186.	25.3	831
111	The Role of Oxygen in Avascular Tumor Growth. PLoS ONE, 2016, 11, e0153692.	2.5	48
112	Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget, 2016, 7, 76613-76627.	1.7	22
113	O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer. Oncotarget, 2016, 7, 83570-83587.	1.7	39
114	Paracrine effect of GTP cyclohydrolase and angiopoietin-1 interaction in stromal fibroblasts on tumor Tie2 activation and breast cancer growth. Oncotarget, 2016, 7, 9353-9367.	1.7	16
115	Does Amifostine Reduce Metabolic Rate? Effect of the Drug on Gas Exchange and Acute Ventilatory Hypoxic Response in Humans. Pharmaceuticals, 2015, 8, 186-195.	4.4	3
116	Autophagosome Proteins LC3A, LC3B and LC3C Have Distinct Subcellular Distribution Kinetics and Expression in Cancer Cell Lines. PLoS ONE, 2015, 10, e0137675.	2.5	138
117	Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget, 2015, 6, 19413-19427.	1.7	39
118	Hypoxia metabolism in ageing. Aging, 2015, 7, 465-466.	2.5	24
119	Estrogen receptor-Î± directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15172-15177.	7.7	114
120	Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress. Cancer Cell, 2015, 27, 57-71.	33.4	607
121	Metabolic and hypoxic adaptation to antiâ€angiogenic therapy: a target for induced essentiality. EMBO Molecular Medicine, 2015, 7, 368-379.	7.2	134
122	A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 2695-2703.	6.4	130
123	A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. Angiogenesis, 2015, 18, 209-217.	7.4	48
124	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). Journal of the National Cancer Institute Monographs, 2015, 2015, 90-96.	2.0	45
125	Carbonic Anhydrase Activity Monitored In Vivo by Hyperpolarized 13C-Magnetic Resonance Spectroscopy Demonstrates Its Importance for pH Regulation in Tumors. Cancer Research, 2015, 75, 4109-4118.	0.6	39
126	Increased expression of transcription factor EB (TFEB) is associated with autophagy, migratory phenotype and poor prognosis in non-small cell lung cancer. Lung Cancer, 2015, 90, 98-105.	2.1	74

#	Article	IF	Citations
127	Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism. Journal of the National Cancer Institute Monographs, 2015, 2015, 81-86.	2.0	7
128	Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1Â and Relation to Clinical Response. Journal of the National Cancer Institute Monographs, 2015, 2015, 64-66.	2.0	5
129	The pH low insertion peptide pHLIP Variant 3 as a novel marker of acidic malignant lesions. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9710-9715.	7.7	60
130	The Role of Histone Demethylase KDM4B in Myc Signaling in Neuroblastoma. Journal of the National Cancer Institute, 2015, 107, .	5.1	62
131	MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1104-1114.	0.7	19
132	Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas. BMC Cancer, 2015, 15, .	3.0	15
133	Scarring, stem cells, scaffolds and skin repair. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, 649-668.	2.8	62
134	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 689-721.	5.3	88
135	Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer. Clinical Cancer Research, 2015, 21, 955-961.	6.4	140
136	Hypoxia induces a lipogenic cancer cell phenotype via HIF1Î±-dependent and -independent pathways. Oncotarget, 2015, 6, 1920-1941.	1.7	60
137	Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. Oncotarget, 2015, 6, 5678-5694.	1.7	33
138	Anoxia. , 2015, , 249-258.		0
139	Anoxia. , 2015, , 1-11.		0
140	Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget, 2014, 5, 5934-5949.	1.7	55
141	ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget, 2014, 5, 6633-6646.	1.7	67
142	JMY protein, a regulator of P53 and cytoplasmic actin filaments, is expressed in normal and neoplastic tissues. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 715-722.	2.7	11
143	Intracellular Carbonic Anhydrase Activity Sensitizes Cancer Cell pH Signaling to Dynamic Changes in CO2 Partial Pressure. Journal of Biological Chemistry, 2014, 289, 25418-25430.	2.3	37
144	Autophagy and lysosomal related protein expression patterns in human glioblastoma. Cancer Biology and Therapy, 2014, 15, 1468-1478.	4.3	77

#	Article	IF	Citations
145	Fatty Acid Uptake and Lipid Storage Induced by HIF-1Î± Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation. Cell Reports, 2014, 9, 349-365.	6.4	505
146	A review of ELTD1, a pro-angiogenic adhesion GPCR. Biochemical Society Transactions, 2014, 42, 1658-1664.	4.2	23
147	Fatty Acid-binding Protein 4, a Point of Convergence for Angiogenic and Metabolic Signaling Pathways in Endothelial Cells. Journal of Biological Chemistry, 2014, 289, 23168-23176.	2.3	83
148	The Notch ligand Jagged1 as a target for anti-tumor therapy. Frontiers in Oncology, 2014, 4, .	2.7	147
149	Informed Consent, Biobank Research, and Locality. Journal of Empirical Research on Human Research Ethics, 2014, 9, 48-55.	1.3	13
150	Functional comparison of Notch ligands in tumour angiogenesis. Asian Pacific Journal of Tropical Disease, 2014, 4, 229.	0.5	0
151	Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Molecular Cancer, 2014, 13, 28.	29.8	131
152	The chemistry, physiology and pathology of pH in cancer. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130099.	4.1	427
153	Inhibitors of Tumor Angiogenesis. , 2014, , 275-317.		1
154	Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nature Genetics, 2014, 46, 376-379.	16.3	256
155	When Cancer Co-opts the Vasculature. New England Journal of Medicine, 2014, 370, 2146-2147.	25.5	3
156	Hypoxia and Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2014, , 1-39.	0.0	36
157	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature Communications, 2014, 5, .	14.1	194
158	TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC. Molecular Cancer Research, 2014, 12, 660-669.	2.9	59
159	Glycogen metabolism in cancer. Biochemical Pharmacology, 2014, 92, 3-11.	5.1	80
160	The Hematopoietic Chemokine CXCL12 Promotes Integration of Human Endothelial Colony Forming Cellâ€“Derived Cells into Immature Vessel Networks. Stem Cells and Development, 2014, 23, 2730-2743.	2.1	19
161	Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells. Journal of Surgical Research, 2014, 190, 203-209.	1.8	10
162	Extensive regulation of the nonâ€coding transcriptome by hypoxia: role of <scp>HIF</scp> in releasing paused <scp>RNA</scp> pol2. EMBO Reports, 2014, 15, 70-76.	5.3	137

#	Article	IF	Citations
163	Proline-Hydroxylated Hypoxia-Inducible Factor 1Î± (HIF-1Î±) Upregulation in Human Tumours. PLoS ONE, 2014, 9, e88955.	2.5	35
164	Clinical Exploitation of Hypoxia. Cancer Drug Discovery and Development, 2014, , 343-359.	0.0	0
165	Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine, 2013, 91, 749-758.	3.6	64
166	Erratum to â€œMicrovessel networks pre-formed in artificial clinical grade dermal substitutes in vitro using cells from haematopoietic tissuesâ€•[Burns 38 (2012) 691â€“701]. Burns, 2013, 39, 194.	2.1	0
167	Overexpression of LC3A autophagy protein in follicular and diffuse large B-cell lymphomas. Hematology/ Oncology and Stem Cell Therapy, 2013, 6, 20-25.	0.7	11
168	A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis. Cancer Cell, 2013, 24, 229-241.	33.4	242
169	A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. Clinical Cancer Research, 2013, 19, 4879-4888.	6.4	188
170	A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2013, 72, 1343-1352.	2.3	34
171	Regulation of intracellular pH in cancer cell lines under normoxia and hypoxia. Journal of Cellular Physiology, 2013, 228, 743-752.	4.2	96
172	An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3. European Journal of Cancer, 2013, 49, 1741-1751.	3.3	12
173	Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer & Metabolism, 2013, 1, .	4.8	206
174	Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiotherapy and Oncology, 2013, 108, 40-47.	0.9	52
175	New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treatment Reviews, 2013, 39, 171-179.	10.1	167
176	Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. European Journal of Cancer, 2013, 49, 156-165.	3.3	37
177	Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. Biochemical Journal, 2013, 449, 389-400.	3.9	126
178	The G-Proteinâ€“Coupled Receptor CLR Is Upregulated in an Autocrine Loop with Adrenomedullin in Clear Cell Renal Cell Carcinoma and Associated with Poor Prognosis. Clinical Cancer Research, 2013, 19, 5740-5748.	6.4	19
179	P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma. Journal of the National Cancer Institute, 2013, 105, 606-607.	5.1	67
180	Changing prognosis of renal cell carcinoma: a single-centre experience over 25 years. Journal of Clinical Urology, 2013, 6, 119-124.	0.3	0

#	Article	IF	Citations
181	Vessel coâ€option in primary human tumors and metastases: an obstacle to effective antiâ€angiogenic treatment?. Cancer Medicine, 2013, 2, 427-436.	2.8	226
182	The use of bioâ€metal concentrations correlated with clinical prognostic factors to assess human breast tissues. X-Ray Spectrometry, 2013, 42, 330-336.	0.9	17
183	Molecular Basis for Jagged-1/Serrate Ligand Recognition by the Notch Receptor. Journal of Biological Chemistry, 2013, 288, 7305-7312.	2.3	26
184	Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cellsin vitro. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 360-369.	5.3	76
185	Microenvironmental Induced Essentiality of Autophagy. Clinical Cancer Research, 2013, 19, 2791-2793.	6.4	2
186	Regulation of Hypoxia Responses by MicroRNA Expression. , 2013, , 267-285.		0
187	The heparan sulfate editing enzyme Sulf1 plays a novel role in zebrafish VegfA mediated arterial venous identity. Angiogenesis, 2013, 17, 77-91.	7.4	16
188	Targeting glycogen metabolism: a novel strategy to inhibit cancer cell growth?. Oncotarget, 2013, 4, 3-4.	1.7	15
189	Molecular Chemotherapy for Breast Cancer. Drugs and Aging, 2012, 14, 75-90.	3.5	8
190	Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer. Clinical Cancer Research, 2012, 18, 3428-3439.	6.4	152
191	Metabolic compartments in tumor tissue: Implications for therapy. Cell Cycle, 2012, 11, 13-13.	3.2	4
192	Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions. Expert Opinion on Therapeutic Targets, 2012, 16, 463-480.	3.9	16
193	Response: Re: Delta-Like Ligand 4-Notch Blockade and Tumor Radiation Response. Journal of the National Cancer Institute, 2012, 104, 421-422.	5.1	0
194	Acid-extrusion from Tissue: The Interplay Between Membrane Transporters and pH Buffers. Current Pharmaceutical Design, 2012, 18, 1331-1337.	2.3	14
195	How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature, 2012, 491, 364-373.	40.1	771
196	Glucose Utilization via Glycogen Phosphorylase Sustains Proliferation and Prevents Premature Senescence in Cancer Cells. Cell Metabolism, 2012, 16, 751-764.	26.3	307
197	ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Research, 2012, 14, .	5.0	46
198	Targeting the ATF4 pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 1189-1202.	3.9	108

#	Article	IF	Citations
199	Microvessel networks in pre-formed in artificial clinical grade dermal substitutes in vitro using cells from haematopoietic tissues. Burns, 2012, 38, 691-701.	2.1	22
200	Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Letters, 2012, 323, 77-87.	8.5	70
201	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	13.8	2,928
202	Clinical Imaging of Tumor Angiogenesis. Future Oncology, 2012, 8, 1443-1459.	2.4	14
203	ATF4 orchestrates a program of BH3-only protein expression in severe hypoxia. Molecular Biology Reports, 2012, 39, 10811-10822.	2.6	26
204	Importance of Intracellular pH in Determining the Uptake and Efficacy of the Weakly Basic Chemotherapeutic Drug, Doxorubicin. PLoS ONE, 2012, 7, e35949.	2.5	90
205	Gene Expression Analysis in Human Breast Cancer Associated Blood Vessels. PLoS ONE, 2012, 7, e44294.	2.5	28
206	Targeting Carbonic Anhydrases with Fluorescent BODIPYâ€Łabelled Sulfonamides. European Journal of Inorganic Chemistry, 2012, 2012, 2898-2907.	1.9	11
207	Carbonic Anhydrase IX Promotes Tumor Growth and NecrosisIn Vivoand Inhibition Enhances Anti-VEGF Therapy. Clinical Cancer Research, 2012, 18, 3100-3111.	6.4	204
208	CD31 angiogenesis and combined expression of HIF-1Î± and HIF-2Î± are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFÎ± transcriptional products are not: implications for antiangiogenic trials and HIFÎ± biomarker studies in primary CC-RCC. Carcinogenesis, 2012, 33, 1717-1725.	2.9	47
209	Expression of vascular Notch ligands Deltaâ€like 4 and Jaggedâ€1 in glioblastoma. Histopathology, 2012, 60, 740-747.	3.9	40
210	High DLL4 expression in tumour-associated vessels predicts for favorable radiotherapy outcome in locally advanced squamous cell head-neck cancer (HNSCC). Angiogenesis, 2012, 16, 343-351.	7.4	15
211	Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. Journal of Clinical Investigation, 2012, 122, 600-611.	9.1	80
212	Gene expression and hypoxia in breast cancer. Genome Medicine, 2011, 3, 55.	9.9	72
213	microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer. Cancer Research, 2011, 71, 5635-5645.	0.6	258
214	Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy. Clinical Cancer Research, 2011, 17, 4892-4900.	6.4	117
215	Nuclear Localization of Factor Inhibitor Hypoxia-Inducible Factor in Prostate Cancer Is Associated With Poor Prognosis. Journal of Urology, 2011, 185, 1513-1518.	4.4	9
216	Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nature Medicine, 2011, 17, 1101-1108.	25.6	524

#	Article	IF	Citations
217	miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors. Molecular Cell, 2011, 41, 210-220.	14.2	363
218	The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1Î± and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Research, 2011, 13, .	5.0	21
219	Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Research, 2011, 13, .	5.0	149
220	Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiotherapy and Oncology, 2011, 99, 424-431.	0.9	148
221	Self assessment of health status and symptoms by cancer patients. International Journal of Pharmacy Practice, 2011, 2, 147-151.	0.5	0
222	Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 372-381.	6.4	81
223	New pathways and mechanisms regulating and responding to Delta-like ligand 4â€“Notch signalling in tumour angiogenesis. Biochemical Society Transactions, 2011, 39, 1612-1618.	4.2	15
224	Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 780-788.	3.7	1,046
225	Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. European Journal of Pharmacology, 2011, 657, 173-183.	4.4	36
226	The angiogenic process as a therapeutic target in cancer. Biochemical Pharmacology, 2011, 81, 1183-1191.	5.1	69
227	The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology, 2011, 68, 1485-1495.	2.3	27
228	Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. BMC Cancer, 2011, 11, .	3.0	23
229	Notch3 signalling promotes tumour growth in colorectal cancer. Journal of Pathology, 2011, 224, 448-460.	5.2	72
230	Expression of hypoxiaâ€associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene. Journal of Pathology, 2011, 225, 63-72.	5.2	36
231	Aberrant succination of proteins in fumarate hydrataseâ€deficient mice and HLRCC patients is a robust biomarker of mutation status. Journal of Pathology, 2011, 225, 4-11.	5.2	232
232	Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitorâ€“Treated ER-Positive Breast Cancer. Clinical Cancer Research, 2011, 17, 3005-3012.	6.4	27
233	Molecular Oncology and the Neoadjuvant Setting: the Perfect Blend for Treatment Personalization and Clinical Trial Design. Journal of the National Cancer Institute Monographs, 2011, 2011, 67-70.	2.0	4
234	Delta-Like Ligand 4â€“Notch Blockade and Tumor Radiation Response. Journal of the National Cancer Institute, 2011, 103, 1778-1798.	5.1	53

#	Article	IF	Citations
235	Notch Regulation of Tumor Angiogenesis. Future Oncology, 2011, 7, 569-588.	2.4	51
236	Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7177-7182.	7.7	168
237	DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo. Cancer Research, 2011, 71, 6073-6083.	0.6	197
238	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute Monographs, 2011, 2011, 147-151.	2.0	57
239	Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles. Journal of the National Cancer Institute Monographs, 2011, 2011, 71-74.	2.0	41
240	Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2Î± and survival. Clinical and Experimental Metastasis, 2011, 29, 11-17.	2.9	10
241	Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer. PLoS ONE, 2011, 6, e20980.	2.5	184
242	p21-activated kinase 1: PAK'ed with potential. Oncotarget, 2011, 2, 491-496.	1.7	47
243	Anoxia. , 2011, , 193-198.		0
244	Diagnostic and Prognostic Cancer Biomarkers: From Traditional to Systems Approaches. , 2011, , 329-366.		0
245	Automated uroâ€oncology data collection: the Cancer Research Uroâ€Oncology Database. BJU International, 2010, 105, 1663-1666.	3.5	7
246	New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood, 2010, 116, 2385-2394.	1.0	332
247	Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica, 2010, 95, 776-784.	4.3	82
248	Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Research and Treatment, 2010, 124, 79-88.	2.5	31
249	Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Research and Treatment, 2010, 123, 795-804.	2.5	11
250	Synchronised phosphorylation of BNIP3, Bcl-2 and Bcl-xL in response to microtubule-active drugs is JNK-independent and requires a mitotic kinase. Biochemical Pharmacology, 2010, 79, 1562-1572.	5.1	18
251	Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. Journal of Cellular and Molecular Medicine, 2010, 14, 18-29.	4.1	133
252	hsaâ€miRâ€210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer, 2010, 116, 2148-2158.	4.4	213

#	Article	IF	Citations
253	Expression of key hypoxia sensing prolylâ€hydroxylases PHD1, â€2 and â€3 in pancreaticobiliary cancer. Histopathology, 2010, 56, 908-920.	3.9	34
254	Effects of HIF-1 and HIF2 on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts. Journal of Oncology, 2010, 2010, 1-14.	1.7	70
255	MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU. PLoS ONE, 2010, 5, e10345.	2.5	267
256	Spectral Clustering of Microarray Data Elucidates the Roles of Microenvironment Remodeling and Immune Responses in Survival of Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2010, 28, 2881-2888.	17.1	65
257	The Histone Demethylase JMJD2B Is Regulated by Estrogen Receptor Î± and Hypoxia, and Is a Key Mediator of Estrogen Induced Growth. Cancer Research, 2010, 70, 6456-6466.	0.6	157
258	Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. Journal of Clinical Pathology, 2010, 63, 867-872.	1.7	79
259	Epigenetic downregulation of human disabled homolog 2 switches TGF-Î² from a tumor suppressor to a tumor promoter. Journal of Clinical Investigation, 2010, 120, 2842-2857.	9.1	83
260	Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability. Cancer Research, 2010, 70, 925-935.	0.6	165
261	HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer. PLoS Biology, 2010, 8, e1000563.	5.2	110
262	Targeting DLL4 in Tumors Shows Preclinical Activity But Potentially Significant Toxicity. Future Oncology, 2010, 6, 1099-1103.	2.4	18
263	Expression of Vascular Notch Ligand Delta-Like 4 and Inflammatory Markers in Breast Cancer. American Journal of Pathology, 2010, 176, 2019-2028.	3.6	102
264	Roles of Tetrahydrobiopterin in Promoting Tumor Angiogenesis. American Journal of Pathology, 2010, 177, 2671-2680.	3.6	29
265	Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Letters, 2010, 296, 194-205.	8.5	46
266	Mechanisms of resistance to antiangiogenesis therapy. European Journal of Cancer, 2010, 46, 1323-1332.	3.3	140
267	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research, 2010, 70, 6268-6276.	0.6	93
268	LC3A-Positive Light Microscopy Detected Patterns of Autophagy and Prognosis in Operable Breast Carcinomas. American Journal of Pathology, 2010, 176, 2477-2489.	3.6	93
269	Endothelial Î±3Î²1-Integrin Represses Pathological Angiogenesis and Sustains Endothelial-VEGF. American Journal of Pathology, 2010, 177, 1534-1548.	3.6	52
270	Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncology, The, 2010, 11, 1172-1183.	21.9	269

#	Article	IF	Citations
271	Human endothelial stem/progenitor cells, angiogenic factors and vascular repair. Journal of the Royal Society Interface, 2010, 7, .	3.4	49
272	The Role of Hypoxia Regulated microRNAs in Cancer. Current Topics in Microbiology and Immunology, 2010, , 47-70.	0.0	30
273	Angiogenesis - still a worthwhile target for breast cancer therapy?. Breast Cancer Research, 2010, 12, .	5.0	11
274	A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biology, 2010, 11, .	8.4	116
275	The Tumor Microenvironment: New Insights into Regulation of Tumor pH by Carbonic Anhydrases. , 2010, , 23-41.		1
276	Overexpression of POLQ Confers a Poor Prognosis in Early Breast Cancer Patients. Oncotarget, 2010, 1, 175-184.	1.7	94
277	Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Frontiers in Bioscience - Landmark, 2009, Volume, 3094.	6.5	106
278	Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Reviews in Molecular Medicine, 2009, 11, .	4.9	178
279	Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer. Cancer Research, 2009, 69, 8472-8481.	0.6	267
280	The Role of Carbonic Anhydrase 9 in Regulating Extracellular and Intracellular pH in Three-dimensional Tumor Cell Growths. Journal of Biological Chemistry, 2009, 284, 20299-20310.	2.3	242
281	Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients. Clinical Cancer Research, 2009, 15, 1046-1051.	6.4	132
282	Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab. Clinical Cancer Research, 2009, 15, 7069-7076.	6.4	49
283	Phosphorylated ERÎ±, HIF-1Î±, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer. Journal of Clinical Oncology, 2009, 27, 227-234.	17.1	102
284	Exon Array Analysis of Head and Neck Cancers Identifies a Hypoxia Related Splice Variant of LAMA3 Associated with a Poor Prognosis. PLoS Computational Biology, 2009, 5, e1000571.	3.3	39
285	A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 4978-4985.	6.4	27
286	Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents. Cancer Research, 2009, 69, 7524-7528.	0.6	74
287	The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib. Cancer Research, 2009, 69, 4415-4423.	0.6	250
288	Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics, 2009, 10, .	3.2	74

#	Article	IF	Citations
289	Nuclear and membrane expression of the angiogenesis regulator deltaâ€like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology, 2009, 54, 598-606.	3.9	16
290	Corrigendum. Histopathology, 2009, 55, 463-464.	3.9	0
291	Role of Hypoxiaâ€inducible Factors in Epigenetic Regulation via Histone Demethylases. Annals of the New York Academy of Sciences, 2009, 1177, 185-197.	4.5	92
292	Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms. Microvascular Research, 2009, 77, 314-326.	2.5	34
293	Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1-39.	5.3	161
294	Hypoxic activation of the unfolded protein response (UPR) induces expression of the metastasis-associated gene LAMP3. Radiotherapy and Oncology, 2009, 92, 450-459.	0.9	78
295	Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood, 2009, 114, 844-859.	1.0	262
296	Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunology, Immunotherapy, 2009, 59, 863-873.	4.7	40
297	Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis, 2008, 11, 41-51.	7.4	82
298	Expression of BNIP3 correlates with hypoxiaâ€inducible factor (HIF)â€1Î±, HIFâ€2Î± and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. Prostate, 2008, 68, 336-343.	2.2	21
299	Phosphorylated VEGFR2/KDR receptors are widely expressed in Bâ€cell nonâ€Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematological Oncology, 2008, 26, 219-224.	2.2	28
300	MicroRNA-10b and breast cancer metastasis. Nature, 2008, 455, E8-E9.	40.1	125
301	Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2diffusion. BJU International, 2008, 101, 22-24.	3.5	57
302	Detection of elevated levels of tumourâ€associated microRNAs in serum of patients with diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2008, 141, 672-675.	2.7	1,473
303	The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecologic Oncology, 2008, 110, 216-221.	1.6	79
304	Hypoxia response and microRNAs: no longer two separate worlds. Journal of Cellular and Molecular Medicine, 2008, 12, 1426-1431.	4.1	170
305	Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Research, 2008, 10, .	5.0	82
306	Phase I Study of Copper-Binding Agent ATN-224 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 7526-7534.	6.4	85

#	Article	IF	Citations
307	Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvascular Research, 2008, 75, 144-154.	2.5	174
308	Activating transcription factor 4. International Journal of Biochemistry and Cell Biology, 2008, 40, 14-21.	2.6	414
309	Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. Cancer Letters, 2008, 262, 87-93.	8.5	21
310	Targeting tumour hypoxia in breast cancer. European Journal of Cancer, 2008, 44, 2766-2773.	3.3	66
311	Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leukemia and Lymphoma, 2008, 49, 2181-2186.	1.6	16
312	A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clinical Cancer Research, 2008, 14, 2601-2608.	6.4	265
313	BHLHB2 ControlsBdnfPromoter 4 Activity and Neuronal Excitability. Journal of Neuroscience, 2008, 28, 1118-1130.	3.7	79
314	Down-Regulation of Phosphatidylinositol 3â€²-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer. Clinical Cancer Research, 2008, 14, 2673-2680.	6.4	49
315	Inhibitors of tumor angiogenesis. , 2008, , 351-381.		0
316	Tumor-associated Carbonic Anhydrase 9 Spatially Coordinates Intracellular pH in Three-dimensional Multicellular Growths. Journal of Biological Chemistry, 2008, 283, 20473-20483.	2.3	181
317	Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 7917-7923.	6.4	334
318	Regulation of CXCR4 by the Notch Ligand Delta-like 4 in Endothelial Cells. Cancer Research, 2008, 68, 1889-1895.	0.6	53
319	hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer. Clinical Cancer Research, 2008, 14, 1340-1348.	6.4	567
320	Measuring Angiogenic Cytokines, Circulating Endothelial Cells, and Endothelial Progenitor Cells in Peripheral Blood and Cord Blood: VEGF and CXCL12 Correlate with the Number of Circulating Endothelial Progenitor Cells in Peripheral Blood. Tissue Engineering - Part C: Methods, 2008, 14, 59-67.	2.6	28
321	Macrophage Infiltration and Angiogenesis in Human Malignancy. Novartis Foundation Symposium, 2008, , 189-204.	1.0	55
322	HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells. PLoS ONE, 2008, 3, e2881.	2.5	65
323	Hypoxic Regulation of Angiogenesis by HIF-1. , 2008, , 169-179.		0
324	The Unfolded Protein Response and Integrated Stress Response to Anoxia: Fig. 1.. Clinical Cancer Research, 2007, 13, 2537-2540.	6.4	45

#	Article	IF	Citations
325	Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptorâ€“Positive Breast Carcinomas Through Genomic Grade. Journal of Clinical Oncology, 2007, 25, 1239-1246.	17.1	665
326	Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers. Cancer Research, 2007, 67, 3441-3449.	0.6	306
327	BNIP3 as a Progression Marker in Primary Human Breast Cancer; Opposing Functions in In situ Versus Invasive Cancer. Clinical Cancer Research, 2007, 13, 467-474.	6.4	78
328	Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer. Clinical Cancer Research, 2007, 13, 550-558.	6.4	12
329	177Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems. Radiochimica Acta, 2007, 95, .	1.4	9
330	Delta-like 4 Notch Ligand Regulates Tumor Angiogenesis, Improves Tumor Vascular Function, and Promotes Tumor Growth In vivo. Cancer Research, 2007, 67, 11244-11253.	0.6	269
331	Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series. Clinical Cancer Research, 2007, 13, 3207-3214.	6.4	776
332	Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Letters, 2007, 253, 74-88.	8.5	44
333	Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?. Trends in Molecular Medicine, 2007, 13, 389-395.	10.0	64
334	Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncology, The, 2007, 8, 488-499.	21.9	61
335	An Investigation Into the Prognostic Significance of Necrosis and Hypoxia in High Grade and Invasive Bladder Cancer. Journal of Urology, 2007, 178, 677-682.	4.4	51
336	Breast tumour angiogenesis. Breast Cancer Research, 2007, 9, .	5.0	141
337	Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Research, 2007, 9, .	5.0	38
338	Transcriptional Profiling of Human Cord Blood CD133+ and Cultured Bone Marrow Mesenchymal Stem Cells in Response to Hypoxia. Stem Cells, 2007, 25, 1003-1012.	3.3	142
339	Macrophages and the hypoxic tumour microenvironment. Frontiers in Bioscience - Landmark, 2007, 12, 4298.	6.5	61
340	The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2Î± but not HIF-1Î±. Prostate, 2007, 67, 623-629.	2.2	27
341	Expression of theforkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia. Prostate, 2007, 67, 1091-1098.	2.2	38
342	Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer and Metastasis Reviews, 2007, 26, 299-310.	7.2	452

#	Article	IF	Citations
343	The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer and Metastasis Reviews, 2007, 26, .	7.2	103
344	Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorÎ² in primary invasive breast carcinomas. Breast Cancer Research and Treatment, 2007, 111, 453-459.	2.5	45
345	Carbonic anhydrase IX unifies spatial pH _i regulation in large cellâ€clusters. FASEB Journal, 2007, 21, .	0.7	0
346	In vivo assessment of Delta likeâ€4 function in tumour development. FASEB Journal, 2007, 21, .	0.7	0
347	Gorham-Stout Syndrome: A Monocyte-Mediated Cytokine Propelled Disease. Journal of Bone and Mineral Research, 2006, 21, 207-218.	5.1	61
348	Introduction on Angiogenesis in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2006, 10, 281-282.	3.2	0
349	The Role of Copper in Tumour Angiogenesis. Journal of Mammary Gland Biology and Neoplasia, 2006, 10, 299-310.	3.2	155
350	Mechanisms of Disease: angiogenesis in urologic malignancies. Nature Reviews Urology, 2006, 3, 157-169.	1.7	44
351	Comparison of Metabolic Pathways between Cancer Cells and Stromal Cells in Colorectal Carcinomas: a Metabolic Survival Role for Tumor-Associated Stroma. Cancer Research, 2006, 66, 632-637.	0.6	370
352	Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. Journal of the National Cancer Institute, 2006, 98, 262-272.	5.1	1,656
353	C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1Î± gene define HIF-1Î± protein expression in non-small cell lung cancer. Lung Cancer, 2006, 53, 257-262.	2.1	33
354	Nuclear Factor-ÎºB Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor-ÎºB DNA-Binding. Clinical Cancer Research, 2006, 12, 3249-3256.	6.4	96
355	Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse. Journal of Clinical Oncology, 2006, 24, 5373-5380.	17.1	955
356	Hypoxia-regulated differentiation: let's step it up a Notch. Trends in Molecular Medicine, 2006, 12, 141-143.	10.0	54
357	The Role of Cell-Free DNA Size Distribution in the Management of Prostate Cancer. Oncology Research, 2006, 16, 35-41.	3.3	26
358	Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood, 2006, 107, 931-939.	1.0	300
359	Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septinâ€…2 in renal cell carcinoma. Proteomics, 2006, 6, 3880-3893.	3.8	52
360	Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Science, 2006, 97, 582-588.	4.0	52

#	Article	IF	Citations
361	Phosphorylated KDR expression in endometrial cancer cells relates to HIF1Î±/VEGF pathway and unfavourable prognosis. Modern Pathology, 2006, 19, 701-707.	5.0	36
362	Phosphorylated KDR can be located in the nucleus of neoplastic cells. Cell Research, 2006, 16, 93-98.	8.2	32
363	Normoxic Stabilization of Hypoxia-Inducible Factor-1Î± by Modulation of the Labile Iron Pool in Differentiating U937 Macrophages: Effect of Natural Resistanceâ€“Associated Macrophage Protein 1. Cancer Research, 2006, 66, 2600-2607.	0.6	81
364	Notch Signaling in Breast Cancer and Tumor Angiogenesis: Cross-Talk and Therapeutic Potentials. Journal of Mammary Gland Biology and Neoplasia, 2006, 11, 41-52.	3.2	62
365	Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecologic Oncology, 2006, 103, 912-918.	1.6	86
366	Niacin induces PPARÎ³ expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochemical Pharmacology, 2006, 71, 646-656.	5.1	84
367	Molecular profiling of signalling proteins for effects induced by the anti-cancer compound GSAO with 400 antibodies. BMC Cancer, 2006, 6, .	3.0	4
368	The relation between hypoxiaâ€inducible factor (HIF)â€1Î± and HIFâ€2Î± expression with anemia and outcome in surgically treated head and neck cancer. Cancer, 2006, 107, 757-766.	4.4	82
369	Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. International Journal of Cancer, 2006, 119, 2539-2545.	4.5	36
370	Effects of Transferrin Receptor Blockade on Cancer Cell Proliferation and Hypoxia-Inducible Factor Function and Their Differential Regulation by Ascorbate. Cancer Research, 2006, 66, 2749-2756.	0.6	63
371	Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. Journal of the National Cancer Institute, 2006, 98, 1183-1192.	5.1	1,011
372	Hypoxia-Inducible Factor-1Î± Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer. Clinical Cancer Research, 2006, 12, 4562-4568.	6.4	214
373	Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients. Journal of Clinical Oncology, 2006, 24, 3623-3628.	17.1	164
374	Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathwayâ€”A Report of the Tumour Angiogenesis Research Group. Journal of Clinical Oncology, 2006, 24, 4301-4308.	17.1	176
375	Endogenous Markers of Two Separate Hypoxia Response Pathways (hypoxia inducible factor 2 alpha) Tj ETQq1 1 0.784314 rgBT /Ove Recruited in the CHART Randomized Trial. Journal of Clinical Oncology, 2006, 24, 727-735.	17.1	243
376	Novel Thioredoxin Inhibitors Paradoxically Increase Hypoxia-Inducible Factor-Î± Expression but Decrease Functional Transcriptional Activity, DNA Binding, and Degradation. Clinical Cancer Research, 2006, 12, 5384-5394.	6.4	43
377	Prognostic Value of an Activation State Marker for Epidermal Growth Factor Receptor in Tissue Microarrays of Head and Neck Cancer. Cancer Research, 2006, 66, 2834-2843.	0.6	48
378	Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Molecular Cancer Therapeutics, 2006, 5, 2193-2202.	1.7	57

#	Article	IF	Citations
379	Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer. Clinical Cancer Research, 2006, 12, 4836-4844.	6.4	120
380	Hypoxia-induced genetic instabilityâ€"a calculated mechanism underlying tumor progression. Journal of Molecular Medicine, 2006, 85, 139-148.	3.6	122
381	Biological Therapies for Metastatic Breast Cancer: Antiangiogenesis. , 2006, , 671-704.		0
382	Notch signaling from tumor cells: A new mechanism of angiogenesis. Cancer Cell, 2005, 8, 1-3.	33.4	106
383	Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. International Journal of Cancer, 2005, 113, 259-266.	4.5	84
384	Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. Journal of Cancer Research and Clinical Oncology, 2005, 131, 741-750.	2.4	137
385	Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium ?Breast Cancer ? the Development and Validation of New Therapeutics?. Breast Cancer Research and Treatment, 2005, 90, 1-3.	2.5	5
386	Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. Journal of Pathology, 2005, 205, 585-591.	5.2	42
387	Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics, 2005, 5, 566-571.	3.8	199
388	Antiangiogenic Therapy. , 2005, , .		0
389	Relation of Erythropoietin and Erythropoietin Receptor Expression to Hypoxia and Anemia in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2005, 11, 7614-7620.	6.4	38
390	Antiangiogenic Activity of a Domain Deletion Mutant of Tissue Plasminogen Activator Containing Kringle 2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 736-741.	6.2	10
391	Up-regulation of Delta-like 4 Ligand in Human Tumor Vasculature and the Role of Basal Expression in Endothelial Cell Function. Cancer Research, 2005, 65, 8690-8697.	0.6	305
392	The Role of Hypoxia-Inducible Factor-1 in Three-dimensional Tumor Growth, Apoptosis, and Regulation by the Insulin-Signaling Pathway. Cancer Research, 2005, 65, 4147-4152.	0.6	38
393	Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma. Clinical Cancer Research, 2005, 11, 1512-1520.	6.4	84
394	The Androgen Receptor Is Significantly Associated with Vascular Endothelial Growth Factor and Hypoxia Sensing via Hypoxia-Inducible Factors HIF-1a, HIF-2a, and the Prolyl Hydroxylases in Human Prostate Cancer. Clinical Cancer Research, 2005, 11, 7658-7663.	6.4	132
395	Prospective Study of Quantitation of Plasma DNA Levels in the Diagnosis of Malignant versus Benign Prostate Disease. Clinical Cancer Research, 2005, 11, 1394-1399.	6.4	93
396	Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1. Clinical Cancer Research, 2005, 11, 3402-3409.	6.4	96

#	Article	IF	Citations
397	Inclusion of Vasculature-Related Variables in the Dukes Staging System of Colon Cancer. Clinical Cancer Research, 2005, 11, 8653-8660.	6.4	32
398	Immunodominance of Poxviral-Specific CTL in a Human Trial of Recombinant-Modified Vaccinia Ankara. Journal of Immunology, 2005, 175, 8431-8437.	0.6	91
399	Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. International Journal of Oncology, 2005, , .	3.6	26
400	Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiotherapy and Oncology, 2005, 75, 89-98.	0.9	115
401	HIF-2Î± expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Experimental Cell Research, 2005, 303, 447-456.	3.1	67
402	Pyruvate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression in Non Small Cell Lung Cancer and Tumor-Associated Stroma. Neoplasia, 2005, 7, 1-6.	7.2	173
403	Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma. Molecular and Cellular Biology, 2005, 25, 5675-5686.	2.5	791
404	HIF-1Î± Induces Genetic Instability by Transcriptionally Downregulating MutSÎ± Expression. Molecular Cell, 2005, 17, 793-803.	14.2	296
405	Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1Î± expression. Modern Pathology, 2005, 19, 9-16.	5.0	44
406	Metabolic profiling of hypoxia-inducible factor-1Î²-deficient and wild type Hepa-1 cells: effects of hypoxia measured by 1H magnetic resonance spectroscopy. Metabolomics, 2005, 1, 293-303.	2.8	12
407	Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification. Clinical Cancer Research, 2004, 10, 7965-7971.	6.4	201
408	Activation of Peroxisome Proliferator-Activated Receptor Î´ Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines. Cancer Research, 2004, 64, 3162-3170.	0.6	155
409	Novel Mechanism of Action for Hydralazine. Circulation Research, 2004, 95, 162-169.	12.8	120
410	BNIP3 Expression Is Linked with Hypoxia-Regulated Protein Expression and with Poor Prognosis in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 5566-5571.	6.4	114
411	A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor Î± Inhibitor in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2004, 10, 6528-6534.	6.4	177
412	c-Myc Interacts with Hypoxia to Induce Angiogenesis In vivo by a Vascular Endothelial Growth Factor-Dependent Mechanism. Cancer Research, 2004, 64, 6563-6570.	0.6	80
413	c-erbB-2 Related Aggressiveness in Breast Cancer Is Hypoxia Inducible Factor-1Î± Dependent. Clinical Cancer Research, 2004, 10, 7972-7977.	6.4	73
414	Antiangiogenic Therapy for von Hippel-Lindau Disease. JAMA - Journal of the American Medical Association, 2004, 291, 943-944.	13.7	60

#	Article	IF	Citations
415	CITED4 Inhibits Hypoxia-Activated Transcription in Cancer Cells, and Its Cytoplasmic Location in Breast Cancer Is Associated with Elevated Expression of Tumor Cell Hypoxia-Inducible Factor 1Î±. Cancer Research, 2004, 64, 6075-6081.	0.6	57
416	Hypoxia-Inducible Factor 1Î± Expression as an Intrinsic Marker of Hypoxia. Clinical Cancer Research, 2004, 10, 8405-8412.	6.4	116
417	Expression of Hypoxia-related Tissue Factors Correlates with Diminished Survival of Adjuvantly Treated Patients with Chromosome 1p Aberrant Oligodendroglial Neoplasms and Therapeutic Implications. Clinical Cancer Research, 2004, 10, 6567-6571.	6.4	12
418	Noninvasive Measurements of Capecitabine Metabolism in Bladder Tumors Overexpressing Thymidine Phosphorylase by Fluorine-19 Magnetic Resonance Spectroscopy. Clinical Cancer Research, 2004, 10, 3863-3870.	6.4	17
419	Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cellâ€“mediated immunotherapy. Journal of Clinical Investigation, 2004, 114, 1800-1811.	9.1	145
420	Expression of the Forkhead Transcription Factor FOXP1 Is Associated with Estrogen Receptor Î± and Improved Survival in Primary Human Breast Carcinomas. Clinical Cancer Research, 2004, 10, 3521-3527.	6.4	82
421	Histological quantitation of tumour angiogenesis. Apmis, 2004, 112, 413-430.	2.6	124
422	Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[11C]-thymidine. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1705, 91-102.	7.1	6
423	Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor. Journal of Biological Chemistry, 2004, 279, 38458-38465.	2.3	878
424	Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 67-71.	0.7	37
425	Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. Journal of Pathology, 2004, 202, 313-320.	5.2	50
426	The hypoxia-regulated transcription factor DEC1(Stra13, SHARP-2) and its expression in human tissues and tumours. Journal of Pathology, 2004, 203, 808-813.	5.2	54
427	Non-linear survival analysis using neural networks. Statistics in Medicine, 2004, 23, 825-842.	1.7	59
428	Hypoxia-inducible factor-1? in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. International Journal of Cancer, 2004, 111, 43-50.	4.5	138
429	Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and Invasion. Cancer Research, 2004, 64, 6160-6165.	0.6	251
430	Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Annals of Medicine, 2004, 36, 530-539.	3.9	101
431	NOVELANGIOGENICSIGNALINGPATHWAYS ANDVASCULARTARGETS. Annual Review of Pharmacology and Toxicology, 2004, 44, 219-238.	12.4	87
432	Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumour: Hypoxia, Survival Pathway and Therapy Target. Cell Cycle, 2004, 3, 159-162.	3.2	230

#	Article	IF	Citations
433	Anoxic induction of ATF-4 through HIF-1â€“independent pathways of protein stabilization in human cancer cells. Blood, 2004, 103, 1876-1882.	1.0	156
434	Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene, 2004, 24, 1212-1219.	6.6	79
435	Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathologica, 2004, 109, 211-216.	7.9	31
436	High Serum YKL-40 Levels in Patients with Primary Breast Cancer is Related to Short Recurrence Free Survival. Breast Cancer Research and Treatment, 2003, 80, 15-21.	2.5	107
437	Necrosis and Hypoxia in Invasive Breast Carcinoma. Breast Cancer Research and Treatment, 2003, 81, 61-69.	2.5	95
438	The Presence of a Fibrotic Focus in Invasive Breast Carcinoma Correlates with the Expression of Carbonic Anhydrase IX and is a Marker of Hypoxia and Poor Prognosis. Breast Cancer Research and Treatment, 2003, 81, 137-147.	2.5	104
439	GLUTâ€1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. International Journal of Cancer, 2003, 104, 85-91.	4.5	189
440	A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). British Journal of Clinical Pharmacology, 2003, 56, 46-56.	2.8	22
441	DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. Journal of Pathology, 2003, 200, 222-228.	5.2	75
442	Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. Journal of Pathology, 2003, 200, 195-206.	5.2	167
443	Expression of the cell death genes BNip3 and NIX in ductal carcinomain situ of the breast; correlation of BNip3 levels with necrosis and grade. Journal of Pathology, 2003, 201, 573-580.	5.2	106
444	Title is missing!. Arthritis Research, 2003, 5, R193.	4.6	156
445	Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10393-10398.	7.7	1,636
446	Comprehensive Proteomic Analysis of Breast Cancer Cell Membranes Reveals Unique Proteins with Potential Roles in Clinical Cancer. Journal of Biological Chemistry, 2003, 278, 6482-6489.	2.3	170
447	Non-Nuclear Localized Human NOSII Enhances the Bioactivation and Toxicity of Tirapazamine (SR4233) in Vitro. Molecular Pharmacology, 2003, 63, 1248-1255.	2.8	25
448	NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells. Journal of Immunology, 2003, 171, 5140-5147.	0.6	417
449	Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2003, 21, 473-482.	17.1	239
450	Angiogenesis in Endocrine Tumors. Endocrine Reviews, 2003, 24, 600-632.	26.0	220

#	Article	IF	Citations
451	Hypoxia-inducible factors 1?? and 2?? are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Research, 2003, 13, 493-501.	1.5	142
452	High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anti-Cancer Drugs, 2003, , 739-744.	1.5	10
453	The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemotherapy and Pharmacology, 2003, 53, 123-128.	2.3	19
454	Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1Î±. Cancer Chemotherapy and Pharmacology, 2003, 53, 8-14.	2.3	26
455	Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes. Brain Pathology, 2003, 13, 133-143.	4.7	120
456	Thymidine Phosphorylase Expression in Gallbladder Adenocarcinomas. International Journal of Surgical Pathology, 2002, 10, 181-188.	1.0	11
457	Differential Gene Expression Patterns in HER2/neu-Positive and -Negative Breast Cancer Cell Lines and Tissues. American Journal of Pathology, 2002, 161, 1171-1185.	3.6	90
458	ROLE OF THYMIDINE PHOSPHORYLASE IN AN IN VITRO MODEL OF HUMAN BLADDER CANCER INVASION. Journal of Urology, 2002, 167, 1482-1486.	4.4	17
459	Drug inhibition of angiogenesis. Current Opinion in Pharmacology, 2002, 2, 403-414.	4.1	62
460	HIF activation identifies early lesions in VHL kidneys. Cancer Cell, 2002, 1, 459-468.	33.4	434
461	Angiogenesis in bladder cancerâ€"prognostic marker and target for future therapy. Surgical Oncology, 2002, 11, 85-100.	2.1	46
462	Preparation of the iodine-124 derivative of the Bolton-Hunter reagent ([124I]I-SHPP) and its use for labelling a VEGF antibody as a PET tracer. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 1077-1090.	0.9	11
463	Association of hypoxiaâ€inducible factors 1Î± and 2Î± with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer, 2002, 95, 1055-1063.	4.4	191
464	Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1192-1202.	0.7	284
465	Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. Journal of Pathology, 2002, 196, 416-422.	5.2	47
466	Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. Journal of Pathology, 2002, 197, 314-321.	5.2	98
467	Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippelâ€Lindau gene and hypoxia. Journal of Pathology, 2002, 198, 502-510.	5.2	80
468	A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene, 2002, 21, 282-290.	6.6	72

#	Article	IF	Citations
469	Hypoxia â€" a key regulatory factor in tumour growth. Nature Reviews Cancer, 2002, 2, 38-47.	24.2	4,408
470	Title is missing!. Journal of Mammary Gland Biology and Neoplasia, 2002, 7, 177-189.	3.2	307
471	Title is missing!. Clinical and Experimental Metastasis, 2002, 19, 673-679.	2.9	12
472	Diagnostic and Prognostic Significance of Tumor Angiogenesis. , 2002, , 151-176.		1
473	ROLE OF THYMIDINE PHOSPHORYLASE IN AN IN VITRO MODEL OF HUMAN BLADDER CANCER INVASION. Journal of Urology, 2002, , 1482-1486.	4.4	1
474	Hypoxia and oxidative stress in breast cancer Hypoxia and tumourigenesis. Breast Cancer Research, 2001, 3, .	5.0	94
475	Measurement of Microvessel Density in Primary Tumors. , 2001, , 115-121.		2
476	Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast. American Journal of Pathology, 2001, 158, 1011-1019.	3.6	204
477	Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncology, The, 2001, 2, 278-289.	21.9	211
478	Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncology, The, 2001, 2, 726-732.	21.9	66
479	Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma. Journal of Clinical Oncology, 2001, 19, 3660-3668.	17.1	377
480	8-Cl-adenosine is an active metabolite of 8-Cl-cAMP responsible for its in vitro antiproliferative effects on CHO mutants hypersensitive to cytostatic drugs. Cancer Chemotherapy and Pharmacology, 2001, 48, 451-458.	2.3	11
481	Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. International Journal of Radiation Oncology Biology Physics, 2001, 50, 27-36.	0.7	100
482	VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. Journal of Pathology, 2001, 193, 325-332.	5.2	49
483	The angiogenic pathway ?vascular endothelial growth factor/flk-1(KDR)-receptor? in rheumatoid arthritis and osteoarthritis. Journal of Pathology, 2001, 194, 101-108.	5.2	82
484	Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. Journal of Pathology, 2001, 195, 236-243.	5.2	39
485	The angiogenic ?vascular endothelial growth factor/flk-1(KDR) receptor? pathway in patients with endometrial carcinoma. Cancer, 2001, 92, 2569-2577.	4.4	66
486	Delta4, an endothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation, 2001, 69, 135-144.	2.4	246

#	Article	IF	Citations
487	Detection of Mammaglobin mRNA in the Plasma of Breast Cancer Patients. Annals of the New York Academy of Sciences, 2001, 945, 192-194.	4.5	25
488	The HIF Pathway: Implications for Patterns of Gene Expression in Cancer. Novartis Foundation Symposium, 2001, , 212-231.	1.0	41
489	Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. Journal of Pathology, 2000, 190, 430-436.	5.2	262
490	â€˜Invading edge vs. innerâ€™ (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. Journal of Pathology, 2000, 192, 140-149.	5.2	51
491	Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene, 2000, 19, 6297-6305.	6.6	226
492	The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochemical Pharmacology, 2000, 59, 993-996.	5.1	37
493	Title is missing!. Clinical and Experimental Metastasis, 2000, 18, 313-319.	2.9	8
494	Cid1, a Fission Yeast Protein Required for S-M Checkpoint Control when DNA Polymerase Î´ or É› Is Inactivated. Molecular and Cellular Biology, 2000, 20, 3234-3244.	2.5	58
495	Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. Cancer Chemotherapy and Pharmacology, 2000, 45, 111-119.	2.3	16
496	Angiogenesis in Pituitary Adenomas and the Normal Pituitary Gland. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1159-1162.	4.4	136
497	A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response. Journal of Immunology, 2000, 165, 6644-6652.	0.6	121
498	von Hippelâ€Lindau Syndrome: Target for Antiâ€Vascular Endothelial Growth Factor (VEGF) Receptor Therapy. Oncologist, 2000, 5, 32-36.	3.6	49
499	The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1Î± and HIF-2Î± in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages. American Journal of Pathology, 2000, 157, 411-421.	3.6	1,116
500	Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Annals of Diagnostic Pathology, 2000, 4, 286-292.	1.2	18
501	Hypoxia signalling in tumour angiogenesis. Expert Opinion on Therapeutic Targets, 2000, 4, 361-375.	1.0	3
502	c-erbB-2 and Episialin Challenge Host Immune Response by HLA Class I Expression in Human Nonâ€“Small-Cell Lung Cancer. Journal of Immunotherapy, 2000, 23, 104-114.	2.4	10
503	Angiogenesis in Pituitary Adenomas and the Normal Pituitary Gland. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1159-1162.	4.4	38
504	von Hippel-Lindau Syndrome: Target for Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Therapy. Oncologist, 2000, 5, 32-36.	3.6	3

#	Article	IF	Citations
505	Title is missing!. Clinical and Experimental Metastasis, 1999, 17, 445-450.	2.9	23
506	Title is missing!. Clinical and Experimental Metastasis, 1999, 17, 545-554.	2.9	44
507	MDM2 and MDMX bind and stabilize the p53-related protein p73. Current Biology, 1999, 9, 829-832.	3.9	108
508	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer, 1999, 85, 1996-2000.	4.4	28
509	Combined role of tumor angiogenesis,bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. , 1999, 86, 1421-1430.		73
510	Angiogenesisvs. response after combined chemoradiotherapy of squamous cell head and neck cancer. , 1999, 80, 810-817.		32
511	Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). , 1999, 189, 351-357.		40
512	URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES. Journal of Urology, 1999, 161, 799-804.	4.4	113
513	eIF4E expression in tumors: its possible role in progression of malignancies. International Journal of Biochemistry and Cell Biology, 1999, 31, 59-72.	2.6	297
514	Angiogenesis in ductal breast carcinoma. Comparison of microvessel density between primary tumour and lymph node metastasis. Cancer Letters, 1999, 137, 145-150.	8.5	25
515	Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet, The, 1999, 353, 1494-1495.	35.3	54
516	Title is missing!. , 1999, .		2
517	Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer, 1999, 85, 1996-2000.	4.4	61
518	Prognostic Significance of Tumor Vascularity. , 1999, , 317-339.		12
519	URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES. Journal of Urology, 1999, , 799-804.	4.4	3
520	Title is missing!. , 1998, 17, 187-194.		116
521	Insulin-like growth factors in human breast cancer. Breast Cancer Research and Treatment, 1998, 52, 175-184.	2.5	73
522	Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?. Breast Cancer Research and Treatment, 1998, 52, 305-319.	2.5	160

#	Article	IF	Citations
523	Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. Clinical and Experimental Metastasis, 1998, 16, 665-672.	2.9	17
524	Title is missing!. Angiogenesis, 1998, 2, 49-55.	7.4	6
525	Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. , 1998, 75, 706-712.		51
526	Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium. , 1998, 185, 402-408.		61
527	Expression of VEGF in routinely fixed material using a new monoclonal. , 1998, 186, 313-318.		64
528	Are angiostatin and endostatin cures for cancer?. Lancet, The, 1998, 351, 1598-1599.	35.3	32
529	Anti-angiogenic therapies in cancer clinical trials. Expert Opinion on Investigational Drugs, 1998, 7, 1629-1655.	4.1	14
530	Angiogenic Polypeptides in Breast Cancer: Expression of Mrnaâ€™s in Primary Human Tumours, MCF-7 Cell Transfection and Xenograft Models. , 1998, , 213-221.		1
531	A Novel Cyclic Adenosine Monophosphate Analog Induces Hypercalcemia via Production of 1,25-Dihydroxyvitamin D in Patients with Solid Tumors. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4044-4048.	4.4	20
532	Resistance to Diverse Drugs and Ultraviolet Light Conferred by Overexpression of a Novel Human 26 S Proteasome Subunit. Journal of Biological Chemistry, 1997, 272, 30470-30475.	2.3	73
533	Association of Tumor Angiogenesis With Bone Marrow Micrometastases in Breast Cancer Patients. Journal of the National Cancer Institute, 1997, 89, 1044-1049.	5.1	98
534	Endothelial Cell-Specific Expression of Tumor Necrosis Factor-Î±from the KDR or E-Selectin Promoters Following Retroviral Delivery. Human Gene Therapy, 1997, 8, 2239-2247.	3.4	50
535	cDNA Cloning of a Humandishevelled DVL-3Gene, Mapping to 3q27, and Expression in Human Breast and Colon Carcinomas. Biochemical and Biophysical Research Communications, 1997, 239, 510-516.	2.1	20
536	Expression of Wnt5a Is Downregulated by Extracellular Matrix and Mutated c-Ha-ras in the Human Mammary Epithelial Cell Line MCF-10A. Biochemical and Biophysical Research Communications, 1997, 239, 911-917.	2.1	23
537	Antiangiogenesis for cancer therapy. Lancet, The, 1997, 349, S13-S15.	35.3	111
538	Isolation of a full-length human WNT7A gene implicated in limb development and cell transformation, and mapping to chromosome 3p25. Gene, 1997, 189, 25-29.	2.4	20
539	A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene, 1997, 14, 1249-1253.	6.6	80
540	Targeting gene expression to hypoxic tumor cells. Nature Medicine, 1997, 3, 515-520.	25.6	324

#	Article	IF	Citations
541	Title is missing!. Journal of Mammary Gland Biology and Neoplasia, 1997, 2, 131-141.	3.2	45
542	Title is missing!. , 1997, 15, 15-28.		59
543	Title is missing!. Angiogenesis, 1997, 1, 36-37.	7.4	12
544	Platelet-derived endothelial cell growth factor (Thymidine Phosphorylase) expression in lung cancer. , 1997, 181, 196-199.		50
545	Potential role ofbcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. , 1997, 74, 565-570.		52
546	Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up. Human Pathology, 1996, 27, 1149-1155.	2.4	88
547	Mechanisms and therapeutic implications of angiogenesis. Current Opinion in Oncology, 1996, 8, 60-65.	2.3	61
548	Breast cancer angiogenesis â€" new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Research and Treatment, 1996, 38, 97-108.	2.5	47
549	EARLY EXPRESSION OF bcl-2 PROTEIN IN THE ADENOMA-CARCINOMA SEQUENCE OF COLORECTAL NEOPLASIA. , 1996, 179, 10-14.		50
550	PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER. Journal of Pathology, 1996, 179, 80-88.	5.2	133
551	TUMOUR ANGIOGENESIS. , 1996, 179, 232-237.		116
552	Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Cancer and Metastasis Reviews, 1996, 15, 221-230.	7.2	16
553	p53 Regulates the Minimal Promoter of the Human Topoisomerase IIÂ Gene. Nucleic Acids Research, 1996, 24, 4464-4470.	16.2	78
554	Regulation of the Human Topoisomerase IIÎ± Gene Promoter in Confluence-arrested Cells. Journal of Biological Chemistry, 1996, 271, 16741-16747.	2.3	78
555	Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Research and Treatment, 1995, 35, 293-297.	2.5	75
556	An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemotherapy and Pharmacology, 1995, 37, 134-138.	2.3	24
557	Plateletâ€derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study. Journal of Pathology, 1995, 176, 183-190.	5.2	165
558	Microvessel count predicts metastatic disease and survival in nonâ€small cell lung cancer. Journal of Pathology, 1995, 177, 57-63.	5.2	152

#	Article	IF	Citations
559	Regulation of Wnt5a mRNA Expression in Human Mammary Epithelial Cells by Cell Shape, Confluence, and Hepatocyte Growth Factor. Journal of Biological Chemistry, 1995, 270, 12851-12856.	2.3	52
560	Re: Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma. Journal of the National Cancer Institute, 1995, 87, 1798-1799.	5.1	9
561	Enhancement of Tumor Growth and Vascular Density by Transfection of Vascular Endothelial Cell Growth Factor Into MCF-7 Human Breast Carcinoma Cells. Journal of the National Cancer Institute, 1995, 87, 213-219.	5.1	231
562	Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis. Journal of Pathology, 1995, 177, 275-283.	5.2	366
563	An Immunohistochemical and Prognostic Evaluation of Cathepsin D Expression in 105 Bladder Carcinomas. Journal of Urology, 1995, 154, 237-241.	4.4	19
564	Potential for protein kinase C inhibitors in cancer therapy. Cancer Treatment and Research, 1995, , 3-27.	0.0	17
565	Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man. International Journal of Radiation Oncology Biology Physics, 1994, 29, 277-283.	0.7	22
566	The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	22
567	What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer?. Breast Cancer Research and Treatment, 1994, 29, 1-2.	2.5	19
568	The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Research and Treatment, 1994, 29, 41-49.	2.5	131
569	Tumor angiogenesis in node-negative breast carcinomas ? relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Research and Treatment, 1994, 29, 109-116.	2.5	149
570	Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer, 1994, 74, 1021-1025.	4.4	31
571	Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma. International Journal of Cancer, 1994, 59, 388-393.	4.5	24
572	bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. British Journal of Cancer, 1994, 69, 135-139.	5.7	274
573	A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Research, 1994, 22, 4884-4889.	16.2	189
574	Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochemical Pharmacology, 1994, 48, 277-285.	5.1	42
575	Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?. European Journal of Cancer, 1994, 30, 201-206.	3.3	26
576	Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treatment Reviews, 1994, 20, 393-412.	10.1	46

#	Article	IF	Citations
577	The role of topoisomerase IIÎ± and Î² in drug resistance. Cancer Treatment Reviews, 1993, 19, 181-194.	10.1	38
578	Cathepsin D levels in primary breast cancers: Relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status. European Journal of Cancer, 1993, 29, 426-428.	3.3	14
579	Angiogenesis in Breast Cancer.. Annals of the New York Academy of Sciences, 1993, 698, 71-84.	4.5	17
580	bcl-2 Protein in Non-Small-Cell Lung Carcinoma. New England Journal of Medicine, 1993, 329, 690-694.	25.5	588
581	Isolation of cDNA clones encoding the Î² isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Research, 1992, 20, 5587-5592.	16.2	218
582	Bladder Cancer â€" Field versus Clonal Origin. New England Journal of Medicine, 1992, 326, 759-761.	25.5	108
583	Mechanisms of Multidrug Resistance in Cancer Treatment. Acta OncolÃ³gica, 1992, 31, 205-213.	1.9	179
584	p53, c-erbB-2 and the Epidermal Growth Factor Receptor in the Benign and Malignant Prostate. Journal of Urology, 1992, 147, 496-499.	4.4	155
585	p53 Expression in Human Breast Cancer. Advances in Cancer Research, 1992, , 69-88.	3.0	32
586	Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. European Journal of Cancer, 1992, 28, 805-810.	3.3	55
587	Reduced topoisomerase II and elevated Î± class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C. Biochemical Pharmacology, 1992, 43, 685-693.	5.1	39
588	A study of adhesion molecules as markers of progression in malignant melanoma. Journal of Pathology, 1992, 167, 187-191.	5.2	46
589	Loss of HLA class-I alleles, heavy chains and Î²2-microglobulin in colorectal cancer. International Journal of Cancer, 1992, 51, 379-385.	4.5	56
590	Novel growth regulatory factors and tumour angiogenesis. European Journal of Cancer & Clinical Oncology, 1991, 27, 781-785.	1.0	130
591	Isolation and properties in culture of human adrenal capillary endothelial cells. Biochemical and Biophysical Research Communications, 1991, 174, 903-908.	2.1	25
592	Interleukin-4 is a potent mitogen for capillary endothelium. Biochemical and Biophysical Research Communications, 1991, 174, 1287-1293.	2.1	84
593	Modulation by verapamil of vincristine pharmacokinetics and sensitivity to metaphase arrest of the normal rat colon in organ culture. Biochemical Pharmacology, 1991, 41, 1217-1225.	5.1	7
594	Growth factors and receptors in cancer. Current Opinion in Biotechnology, 1991, 2, 260-268.	7.6	3

#	Article	IF	Citations
595	Telling changes of base. Nature, 1991, 350, 377-378.	40.1	49
596	Assessment of renal toxicity by urinary enzymes in patients receiving chemotherapy with 8-methyl-8-acetylenic-putrescine. Cancer Chemotherapy and Pharmacology, 1990, 26, 65-66.	2.3	0
597	Mutant p53â€"the commonest genetic abnormality in human cancer?. Journal of Pathology, 1990, 162, 5-6.	5.2	113
598	The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 1990, 65, 1619-1625.	4.4	299
599	Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. Cancer, 1990, 65, 2421-2425.	4.4	20
600	Enhancement of adriamycinÂ® cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha1 acid glycoprotein. European Journal of Cancer & Clinical Oncology, 1990, 26, 432-436.	1.0	21
601	Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 811-814.	2.4	127
602	The quantitation by radioimmunoassay of 2â€²-deoxyuridine 5â€²-triphosphate in extracts of thymidylate synthase-inhibited cells. Analytical Biochemistry, 1989, 177, 347-352.	2.5	12
603	Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. Cancer Chemotherapy and Pharmacology, 1989, 23, 252-254.	2.3	7
604	Defective repair of DNA single- and double-strand breaks in the bleomycin- and X-ray-sensitive Chinese hamster ovary cell mutant, BLM-2. Mutation Research DNA Repair, 1989, 217, 93-100.	3.7	14
605	A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. European Journal of Cancer & Clinical Oncology, 1989, 25, 911-912.	1.0	27
606	Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer. European Journal of Cancer & Clinical Oncology, 1989, 25, 1105-1111.	1.0	13
607	Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu. The Journal of Steroid Biochemistry, 1989, 34, 123-131.	1.3	125
608	Modulation of dipyridamole action by Î±1acid glycoprotein. Biochemical Pharmacology, 1989, 38, 3281-3288.	5.1	16
609	Chemotherapy induced emesis may exacerbate the nephrotoxicity of combined ifosfamide/mesna and cisplatin chemotherapy. European Journal of Cancer & Clinical Oncology, 1989, 25, 917-918.	1.0	2
610	Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. Biochemical Pharmacology, 1988, 37, 2113-2120.	5.1	15
611	Adenosine-diphosphoribosyltransferase inhibitors can protect against or potentiate the cytotoxicity of S-phase acting drugs. Biochemical Pharmacology, 1988, 37, 2155-2160.	5.1	8
612	Bleomycin and X-ray-hypersensitive Chinese hamster ovary cell mutants: Genetic analysis and cross-resistance to neocarzinostatin. Mutation Research - DNA Repair Reports, 1988, 193, 157-165.	2.1	4

#	Article	IF	Citations
613	Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer. European Journal of Cancer & Clinical Oncology, 1988, 24, 733-736.	1.0	41
614	The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16â€“213, doxorubicin and vincristine (VPAV) for small cell lung cancer. European Journal of Cancer & Clinical Oncology, 1988, 24, 123-129.	1.0	28
615	Plasma prostaglandins in lung cancer. European Journal of Cancer & Clinical Oncology, 1988, 24, 1069-1071.	1.0	8
616	False-positive ketonuria during ifosfamide and mesna therapy. European Journal of Cancer & Clinical Oncology, 1986, 22, 229-230.	1.0	6
617	To branch or to expand?. ELife, 0, 5, .	1.6	2
618	Atf4. The AFCS-nature Molecule Pages, 0, , .	2.0	0